Coya Therapeutics Completes Enrollment of 120 Patients in COYA 302 ALS Trial
Coya Therapeutics completes enrollment of 120 patients in COYA 302 ALS trial testing an immunomodulatory approach to slow neuroinflammation.
Lundbeck’s Lu AF28996 gains 2+ hours daily ON-time in Parkinson’s Phase Ib
Lu AF28996 gains over 2 hours of daily ON-time in Parkinson's Phase Ib trial, with meaningful reductions in troublesome...
Tekton Research St. Louis Site Exceeds Enrollment in Alzheimer’s Trial
Tekton Research's St. Louis site exceeded its enrollment goal in an Alzheimer's trial despite joining mid-stream as a rescue...
VenaSeal Cyanoacrylate Closure Heals 88% of Venous Leg Ulcers in 24-Month Study
VenaSeal cyanoacrylate closure healed 88% of venous leg ulcers with 92-day median healing time in 24-month study of excluded...
Symphony RCT Shows 55% Closure Rate in Diabetic Foot Ulcers at 12 Weeks
Symphony RCT shows 55% closure rate in diabetic foot ulcers at 12 weeks, outperforming standard care alone with faster...
AnnJi Advances AJ201 Into Phase 3 Trial for Kennedy’s Disease
AnnJi advances AJ201 into Phase 3 trial for Kennedy's disease, targeting 200 ambulatory patients globally with a potential first-in-class...
CRScube Acquires Mednet to Expand AI-Assisted Data Entry in Clinical Trials
CRScube acquires Mednet to deploy AI-assisted data entry in clinical trials, reducing manual transcription errors and query cycles at...
Disconnected systems hinder RBQM adoption in clinical trials, FDA compliance
Only 57% of clinical trial organizations have adopted risk-based quality management, with disconnected systems creating regulatory compliance gaps for...
Niia Signature Patch Shows 20-Minute Glucose Signal Recovery After Insulin Bolus
Niia Signature Patch achieves 20-minute glucose signal recovery after insulin bolus, addressing a key challenge in all-in-one diabetes patches.
DHHS Releases 2026 Unified Agenda With Five Clinical Research Rule Changes
DHHS 2026 Unified Agenda proposes five clinical research rule changes affecting Phase 1 INDs, single IRB requirements, and human...